News

Press Releases

Dec 08, 2023

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Dec 04, 2023

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Nov 16, 2023

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Nov 06, 2023

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Presentations

Jun 11, 2023

EHA 2023 (Exa-cel)

Apr 27, 2023

2022 Statutory Financial Statements

Apr 27, 2023

2022 Compensation Report

Apr 27, 2023

2022 Annual Report

View All Presentations

Events

Wednesday, June 13, 2018 8:00 a.m. PT

CRISPR Therapeutics at Goldman Sachs 39th Annual Global Healthcare Conference

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.